Sonoma Pharmaceuticals Inc SNOA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNOA is a good fit for your portfolio.
News
-
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
-
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
-
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
-
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
-
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $0.16
- Day Range
- $0.15–0.17
- 52-Week Range
- $0.12–1.52
- Bid/Ask
- $0.16 / $0.17
- Market Cap
- $2.48 Mil
- Volume/Avg
- 108,630 / 563,583
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 171
- Website
- https://www.sonomapharma.com
Valuation
|
Metric
|
SNOA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.33 |
Price/Sales | 0.08 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SNOA
|
|---|---|
Quick Ratio | 1.72 |
Current Ratio | 4.07 |
Interest Coverage | — |
Quick Ratio
SNOA
Profitability
|
Metric
|
SNOA
|
|---|---|
Return on Assets (Normalized) | −30.51% |
Return on Equity (Normalized) | −68.39% |
Return on Invested Capital (Normalized) | −62.90% |
Return on Assets
SNOA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Llvwmqgyw | Mzzjh | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Blcttqgzj | Nnccb | $70.8 Bil | |
HLN
| Haleon PLC ADR | Phcpvydgv | Tcgn | $38.2 Bil | |
VTRS
| Viatris Inc | Cxkqxjrn | Xsp | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Xyjfynkl | Cljy | $12.5 Bil | |
CTLT
| Catalent Inc | Wkpnvlyv | Flkjl | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Nzznbmbm | Kpv | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Tqdmzrwf | Lyyw | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Pgkqsvtq | Pmghcd | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Klzcrkfty | Xzqmw | $2.9 Bil |